The study indicates that abnormal overexpression of PCSK9 enhances cell proliferation and confers resistance to sorafenib in hepatocellular carcinoma by facilitating AKT-S473 phosphorylation (131). The gene discussed is PCSK9; the disease is hepatocellular carcinoma.